Anticancer Activity of Selenium Nanoparticles In Vitro Studies

dc.creatorMartínez Esquivias, Fernando
dc.creatorGutiérrez Angulo, Melva
dc.creatorPérez Larios, Alejandro
dc.creatorSánchez Burgos, Jorge
dc.creatorBecerra Ruíz, Julieta
dc.creatorGuzmán Flores, Juan Manuel
dc.date2021-10-13T21:00:24Z
dc.date2021-10-13T21:00:24Z
dc.date2021-09
dc.date.accessioned2023-07-21T21:43:52Z
dc.date.available2023-07-21T21:43:52Z
dc.identifierMartínez Esquivias F., Gutiérrez Angulo M., Pérez Larios A., SánchezBurgos J., Becerra Ruiz J. and Guzmán Flores J.M. (2021) “Anticancer Activity of Selenium Nanoparticles In Vitro Studies”, Anti-Cancer Agents in Medicinal Chemistry 2021; 21() . https://doi.org/10.2174/1871520621666210910084216
dc.identifier1875-5992
dc.identifier1871-5206
dc.identifierDOI: 10.2174/1871520621666210910084216
dc.identifierhttp://repositorio.cualtos.udg.mx:8080/jspui/handle/123456789/1147
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7752628
dc.descriptionArtículo
dc.descriptionHealth systems worldwide consider cancer a disease that causes the highest number of deaths per year. The low efficacy of current cancer therapies has led other areas of science to search for new alternatives, including nanomaterial sciences. Selenium nanoparticles have anticancer activity, as revealed by in vitro tests performed on prostate, breast, cervical, lung, colorectal, and liver cancer cell lines. Studies attribute anticancer activity to the anti-metastatic effect due to the inhibition of migration and invasion processes. The antiproliferative effect is the low expression of molecules such as cyclin D1, cyclin E, and CDK2. In addition to the activation of cell apoptosis by caspase-dependent mechanisms, there is a low expression of anti-apoptotic proteins such as Bcl-2 and a high expression of the apoptotic proteins like Bax and Bad. Other studies attribute anticancer activity to the activation of cell necroptosis, where molecules such as TNF and IRF1 participate. The pharmacological potential of selenium nanoparticles depends primarily on the administered dose, particle size, and chemical composition. Furthermore, several studies have shown that the administration of these nanoparticles is safe due to their low toxicity in non-cancerous cells. In this review, the most relevant antecedents on the anticancer potential of selenium nanoparticles in prostate, breast, cervical, lung, liver, and colorectal cancer cell lines are discussed.
dc.languageen
dc.publisherBentham Science
dc.relationAnti-Cancer Agents in Medicinal Chemistry;Volume 21, 18 Issues
dc.subjectselenium nanoparticles
dc.subjectanticancer
dc.subjectprostate
dc.subjectbreast
dc.subjectcervical
dc.subjectlung
dc.subjectcolorectal
dc.titleAnticancer Activity of Selenium Nanoparticles In Vitro Studies
dc.typeArticle


Este ítem pertenece a la siguiente institución